Arimidex Articles
AstraZeneca offering Arimidex for just $40 a month in USA
16 February 2012
Aromatase inhibitors may increase risk of heart disease in postmenopausal women with breast cancer
10 December 2010
AstraZeneca sees strong earnings and revenue growth in2009 but a slowdown in 4th qtr
28 January 2010
Mylan confirms first-to-file patent challenge to Cephalon’s sleep-disorder drug Nuvigil
12 January 2010
Positive new data Ph III on AstraZeneca’s Faslodex presented at SABC; drugmaker seeks more partnerships
11 December 2009
AstraZeneca beats consensus forecasts with 3rd quarter 2009 profits up 22% raises forecasts
29 October 2009
Stock Commentary - Europe - week to Mar 16, 2009
23 March 2009
AstraZeneca analysis shows Arimidex superior to tamoxifen in sub-groups of breast cancer patients
23 March 2009
Novartis drug cuts breast cancer death by 36%
2 March 2009
AstraZeneca's net income slips 1.6% in 4th qtr as generic competition starts to bite
9 February 2009
Highlights of first PDCO meeting of 2009
26 January 2009
AZ's Faslodex improves disease control
22 December 2008
Side effects may be good in breast cancer
10 November 2008
AstraZeneca's net profit falls 12% on restructing charges from MedImmune buy, lower Nexium sales
11 February 2008
Arimidex cuts breast cancer recurrence 24% vs tamoxifen
24 December 2007
Arimidex gets 6-month US patent extension
10 December 2007
Arimidex is "cost effective" on NICE model
23 July 2007
Bondronat prevents bone loss in cancer patients
11 June 2007
AstraZeneca's CEO reviews Japan ops
5 March 2007
Long-term ATAC data supports Arimidex over tamoxifen
22 December 2006
Arimidex plus Herceptin improve survival in co-positives
22 December 2006
First Parallel imports hit French market
18 December 2006
Patients benefit after switch to Arimidex
27 November 2006
Aromatase inhibitors approved by UK's NICE
27 November 2006
AstraZeneca's offer to Medicare Part D enrollees
20 November 2006
Israeli NHI Ombudswoman's complaints report
4 September 2006
AIs are best option for breast cancer, says panel
7 August 2006
Stock Commentary - Europe - week to May 29, 2006
5 June 2006
UK's NICE gives AI's tentative approval
29 May 2006
Japan stock market week to April 24, 2006
1 May 2006
Faslodex as advanced breast cancer drug
13 March 2006
AstraZeneca's 4th-qtr profit leaps 30% but firm admits thin pipeline
13 February 2006
AstraZeneca profit leaps 30% but firm admits thin pipeline
6 February 2006
AstraZeneca's Arimidex improves cancer survival vs tamoxifen
19 December 2005
AstraZeneca's Faslodex and Arimidex little different
19 December 2005
Scotland OKs Arimidex
19 September 2005
US FDA gives priority review to Novartis' Femara in new indication
5 September 2005
NZ Pharmac gets budget boost, OKs new Rx uses
8 August 2005
Astra Zeneca 2nd-qtr pretax profit leaps 67%
8 August 2005
AstraZeneca sees 2nd-qtr pretax profit leap 67%
1 August 2005
AstraZeneca's Arimidex gets new indication
4 July 2005
ASCO recommends AI's in treatment of early breast cancer
22 November 2004
AstraZeneca's EPS up 56%, sales rise 10%
1 November 2004
AstraZeneca's 2nd-qtr sales jump 19%
2 August 2004
AstraZeneca forecasts good growth in Spain
3 May 2004
AstraZeneca's 1st-qtr sales pass $5 billion
3 May 2004
Stock Commentary - Europe
29 March 2004
Arimidex could avoid breast removal
29 March 2004
Aromasin prolongs breast cancer survival
29 March 2004
AstraZeneca's Faslodex meets unmet need in breast cancer
29 March 2004
AstraZeneca forecasts sharp rise in earnings but shares slip on mediocre Crestor sales
9 February 2004
Positive results for Arimidex
15 December 2003
Cancer test to predict tamoxifen and anastrazole response
10 November 2003
New large-scale breast cancer prevention trial starts
6 October 2003
AstraZeneca raises full-year earnings guidance
28 July 2003
Arimidex versus tamoxifen trials planned
9 June 2003
ATAC study supports AstraZeneca Arimidex
24 March 2003
IVAX gets US go-ahead for generic Nolvadex
3 March 2003
Serono sees 15%-20% growth for 2003
10 February 2003
AstraZeneca sales rise 6.9% in 2nd quarter
5 August 2002
Serono/AstraZeneca deal on anastrozole
29 July 2002
Novartis Glivec works in early-stage CML
27 May 2002
Update: IDEAL data for AstraZeneca's Iressa
27 May 2002
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
